Last updated on November 2017

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers


Brief description of study

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

Detailed Study Description

A Phase 1 & 2 Study of the Safety, Tolerability and Efficacy of Varlilumab Administered in Combination With Nivolumab in Advanced Refractory Solid Tumors (Head and Neck, Renal, Ovarian and others).

Eligible patients will be enrolled and receive varlilumab in combination with nivolumab (Opdivo).

All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.

Clinical Study Identifier: TX9633

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Branimir Sikic, MD

The Stanford Center for Clinical and Translational Education and Research Recruiting
Palo Alto, CA USA
  Connect »